Company Overview of Hyperion Therapeutics, Inc.
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.
2000 Sierra Point Parkway
Brisbane, CA 94005
Founded in 2006
Key Executives for Hyperion Therapeutics, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Principal Accounting Officer
Chief Commercial Officer and Senior Vice President
Chief Legal Officer, Senior Vice President of Government Affairs and Secretary
Emeritus Chief Medical Officer
Compensation as of Fiscal Year 2015.
Hyperion Therapeutics, Inc. Key Developments
Hyperion Therapeutics, Inc.(NasdaqGM:HPTX) dropped from NASDAQ Biotechnology Index
May 8 15
Hyperion Therapeutics, Inc. will be removed from NASDAQ Biotech Index.
Hyperion Therapeutics, Inc. Announces Amendments to Certificate of Incorporation
May 7 15
Hyperion Therapeutics, Inc. announced amended and restated certificate of incorporation. Article 1: Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require. ARTICLE II: Section 3. Corporate Seal. The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, Corporate Seal-Delaware. ARTICLE III: Place of Meetings. Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (DGCL).
Hyperion Therapeutics, Inc.(NasdaqGS:HPTX) dropped from NASDAQ Composite Index
May 7 15
Hyperion Therapeutics, Inc. will be removed from Nasdaq Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 30, 2015
Most Searched Private Companies
Sponsored Financial Commentaries